Form 4: Amgen SVP Nancy Grygiel Reports Stock Transaction

Amgen Inc. SVP and CCO Nancy A. Grygiel reported the disposition of 88 shares of common stock to cover tax obligations.

Summary

• Nancy A. Grygiel, SVP & CCO of Amgen Inc., disposed of 88 shares of common stock on May 7, 2026.
• The transaction was executed at a price of $331.11 per share.
• The disposition was made to satisfy tax withholding obligations related to the vesting of equity awards.
• Following the transaction, the reporting person maintains direct ownership of 7,330 shares.
• The reporting person also holds 106.1864 shares indirectly through a 401(k) plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction is purely administrative and related to tax obligations.

Positives

• The transaction is a routine administrative action related to tax withholding rather than a discretionary sale.

Negatives

• None identified; this is a standard regulatory disclosure for executive compensation tax compliance.

Risks

• None identified.

Future Outlook

Not applicable; this is a retrospective disclosure of an insider transaction.

Industry Context

StockSavvy.ai notes that routine Form 4 filings regarding tax withholding are standard practice for executives in the biotechnology sector and do not typically signal changes in corporate strategy or management sentiment.

Comparison to Industry Standards

• The transaction aligns with standard executive equity compensation practices observed at large-cap pharmaceutical companies like Pfizer, Merck, and Gilead Sciences.

Stakeholder Impact

• No material impact on shareholders, employees, or creditors.

Key Dates

Keywords

Amgen, AMGN, Insider Trading, Form 4, Executive Compensation, Biotechnology